Search Details

Word: blockers (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

...play of two juniors--6'6" guard Sea Lonergan and 7'0" center Brian Gilpin. Lonergan led the Ancient Eight in scoring last season at 17.3 points per game while shooting 43.7 percent from three-point land. And aside from being the team's leading rebounder and shot-blocker, Gilpin's size alone makes him an all-around intimidator in the paint...

Author: By Jamal K. Greene, | Title: M. Cagers Host Dartmouth | 12/12/1995 | See Source »

...Tagamet] is to shore up the battlements before Zantac," says Susan Coleman, managing partner of NCI Consulting in Princeton, New Jersey. When Zantac 75 wins approval for over-the-counter sales in the U.S., she predicts, "World War III starts." She notes that while other over-the-counter acid blockers had been on the British market for a year before Zantac 75 appeared in January, it took only three months to overwhelm the competition. "Zantac on the market will be a significant competitor," says Robert Kniffin, vice president of Johnson & Johnson's external communications. "We shall see." (As if Zantac...

Author: /time Magazine | Title: FIRE IN THE BELLY, MONEY IN THE BANK | 11/6/1995 | See Source »

Introduced in the U.S. by SmithKline Beecham in 1977 and under patent protection for 17 years, Tagamet was the pioneer acid blocker. Worldwide it has earned the company a total of $14 billion and was the first drug ever to chalk up $1 billion in sales in a single year. But in the late 1980s, anticipating the worst when its Tagamet patent ran out in 1994, SmithKline began conducting clinical trials and seeking FDA approval of an over-the-counter version. The wisdom of that decision became evident when Tagamet sales plummeted from $600 million in 1993 to only...

Author: /time Magazine | Title: FIRE IN THE BELLY, MONEY IN THE BANK | 11/6/1995 | See Source »

...Pepcid's quick strike, Tagamet's ambitious counterattack and the row over advertising may look like mere skirmishes when Zantac 75 enters the fray. This acid blocker is the over-the-counter version of Zantac, the top-selling prescription drug in the world and the pride of Britain's Glaxo-Wellcome pharmaceutical stable. Prescribed for 240 million patients around the globe, Zantac last year generated $3.6 billion in sales, $2.1 billion in the U.S. And last month the over-the-counter Zantac 75 received a recommendation from an FDA advisory committee, virtually assuring its imminent approval for sale...

Author: /time Magazine | Title: FIRE IN THE BELLY, MONEY IN THE BANK | 11/6/1995 | See Source »

...products. In touting Tagamet HB, for example, SmithKline has to avoid invidious comparisons with Tums, its antacid moneymaker, while J&J/Merck must tiptoe around any comparisons between Pepcid AC and its antacid, the much advertised Mylanta. Meanwhile, Switzerland's Ciba-Geigy has other worries. Though it has no acid blocker available that could bite into sales of Maalox, its bread-and-butter antacid, its competitors' new drugs almost certainly will...

Author: /time Magazine | Title: FIRE IN THE BELLY, MONEY IN THE BANK | 11/6/1995 | See Source »

Previous | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | Next